omidubicel (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Allogeneic Hematopoietic Stem Cell Transplantation

Pending FDA approval for patients with blood cancers in need of an allogenic hematopoietic stem cell transplant

Next:

Pharmacology

Mechanism of Action

Omidubicel consists of ex vivo-expanded umbilical cord blood-derived allogeneic hematopoietic CD34-positive progenitor cells (HCPs)

Can be used during transplantation; these cells can differentiate into a variety of cell types including fibroblasts, osteoblasts, chondrocytes, myocytes, adipocytes, and endothelial cells

Compared to bone marrow transplants, these HPCs have decreased risk of causing graft-versus host disease (GvHD), increased survival, and enhanced transplant and engraftment potential for any given patient as there is no need for a matched donor

Previous
Next:

Images

Pricing & Images are not currently available for this monograph.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.